Immune Mediators of Chronic Pelvic Pain Syndrome|
Prostatitis types IIIa and IIIb are classified according to the presence of pain without concurrent presence of bacteria; however, it is becoming more evident that, although levels of bacteria are not directly associated with levels of pain, the presence of bacteria might act as the initiating factor that drives primary activation of mast-cell-mediated inflammation in the prostate. [Nat Rev Urol]
Visit our reviews page to see a complete list of reviews in the human immunology research field.
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer|
Oncothyreon Inc. announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase III START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer. [Oncothyreon Inc.]
Immunicum Submits the Final Report for its Phase I/II Trial in Metastatic Renal Cell Carcinoma Showing Positive Safety Data and Promising Survival Data
Immunicum® AB submitted the final report to the Swedish Medical Products Agency regarding its clinical Phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. [Immunicum AB]
Global Partners SillaJen, Transgene and Lee’s Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec
Transgene SA Lee’s Pharmaceutical and SillaJen unveiled their late-stage clinical development plan for Pexa-Vec oncolytic immunotherapy. The companies plan to initiate a global Phase III study in the first-line treatment of advanced hepatocellular carcinoma patients, as well as several additional Phase I/II trials in different cancers, both as a single agent and in combination with a variety of other treatments, including immunotherapies such as immune checkpoint inhibitors. [Transgene SA]
Adaptimmune Integrates BioLife Solutions CryoStor® Cell Freeze Media in Cancer Immunotherapy Clinical Trial
BioLife Solutions, Inc. announced that Oxford, UK and Philadelphia, PA-based Adaptimmune Ltd has adopted the Company’s CryoStor clinical grade cell freeze media for use in Adaptimmune’s current Phase I/II clinical trial CT Antigen TCR-Engineered T Cells for Myeloma. [BioLife Solutions, Inc.]
Have we missed an important article or publication in Human Immunology News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.